Panacea Biotech stock shoots up 5% post Q3FY22 numbers

16 Feb 2022 , 03:55 PM

Panacea Biotech announced its quarterly standalone and consolidated numbers and has reported a significant decline in its revenue and profits.

Its consolidated net sales were Rs155.88 crore for Q3FY22 against Rs141.76 crore for Q3FY21, up by 9.96% yoy. Whereas loss for the current quarter increased to Rs49.20 crore against a loss of Rs40.05 in the previous corresponding quarter.

Consolidated EBITDA for the quarter ended December 2021 declined 20.66% yoy at Rs13.52 crore against Rs17.04 crore in the quarter ended December 2020.

Company’s standalone net sales plunged by 44.25% yoy at Rs38.48 crore for Q3FY22 against Rs69.02 in the previous corresponding quarter. Company’s net loss widened majorly to Rs22.43 crore in the quarter ended December 2021 against loss of Rs1.90 crore in the previous corresponding quarter.

Standalone EBITDA reported was also negative at Rs14.06 crore for the quarter under review against Rs10.40 crore for the same quarter last year, down by 234.67% yoy.

Its standalone EPS narrowed to negative Rs3.66 per share in Q3FY22.

Panacea Biotech closed 4.99% higher in today’s trade at Rs202.10, against its previous closing price of Rs192.50 on NSE. It touched intraday high and low of Rs202.10 and Rs194.40 respectively.